ADARx Pharmaceuticals (ADRX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.74

Estimate

-$0.25

Surprise

-585.9%

Revenue (period 2026-09-30)

$2.2M

Score today

5.7/10

Revenue source: xbrl.

ADARx Pharmaceuticals (ADRX) reported a wider loss than forecast — adjusted EPS of -$1.74 against the -$0.25 estimate (a 585.9% shortfall).

• ADARx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates — fiscal.ai, 2026-11-12
• Adarx Pharmaceuticals Q3 EPS $(1.74) Misses $(0.31) Estimate, Sales $2.200M Miss $2.583M Estimate — benzinga, 2026-11-12

TrendMatrix currently rates ADRX Sell at 5.7/10; no pre/post engine snapshot brackets this report.

0 of the last 1 quarters beat the estimate; this quarter's -585.9% surprise compares with a -585.9% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$14.20

Price target

$29.11

Stop

$13.21

Upside to target

+105.0%

Reward-to-risk

7.0:1

Model outputs from TrendMatrix’s engine as of 2026-11-15 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.57B

P/E (fwd)

-9.4

52-week range

$12.50–$23.21

Off 52-week high

38.8%

RSI (14)

31

Volume vs avg

1.33×

Score today

5.7/10